Incidence of Adjuvant Radiation Therapy after Radical Hysterectomy and Preoperative Prognostic Factors in Cervical Cancer Patients (Stage IA2-IIA1) in Lampang Hospital, Ten Years’ Experience
Keywords:
Uterine Cervical Neoplasms, Radical Hysterectomy, Radiotherapy, AdjuvantAbstract
Introduction: For early-stage cervical cancer (IA2–IIA1), radical hysterectomy with pelvic lymphadenectomy and primary chemoradiation offer comparable cure rates. However, some patients require adjuvant radiation therapy after surgery. Combined modality therapy can lead to significant long-term complications.
Objectives: The objective of this study is to evaluate the incidence of adjuvant radiation therapy after radical hysterectomy and to identify preoperative prognostic factors in early-stage cervical cancer (stages IA2–IIA1) at Lampang Hospital.
Materials and Method: This retrospective cohort study included early-stage cervical cancer patients who underwent radical hysterectomy with pelvic lymphadenectomy (2014–2023). Preoperative risk factors for adjuvant radiotherapy, including tumor size, diagnostic method, tumor type, vaginal bleeding, and suspected vaginal invasion, were analyzed using univariate and multivariate logistic regression in Stata 18.0.
Results: Out of 173 patients, 69 (39.9%) received postoperative adjuvant radiotherapy. Preoperative vaginal bleeding (aOR 2.48, 95% CI: 1.21-5.06; p = 0.013) and suspected vaginal invasion (aOR 10.92, 95% CI: 1.23-97.09; p = 0.032) were significantly associated with the need for adjuvant radiation therapy after radical hysterectomy. Tumor size > 4 cm was associated with an increased risk in the univariable analysis (OR 2.76, p = 0.016). Other factors, including non-SCCA histology and gross lesions, showed trends toward increased risk but did not reach statistical significance.
Conclusion: At Lampang Hospital, 39.9% of patients received postoperative radiation therapy after radical hysterectomy. Preoperative clinical examinations alone are insufficient to predict radiation therapy needs. Advanced imaging techniques, such as CT or MRI, are used to aid in treatment planning. In resource-limited settings, evaluations should focus on high-risk patients with vaginal bleeding, suspected vaginal invasion, or tumors > 4 cm.
References
Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. The Lancet. 1997; 350 (9077): 535-40. https://doi.org/10.1016/S0140-6736(97)02250-2
Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J Gynecol Oncol. 2017; 28 (3): e34. https://doi.org/10.3802/jgo.2017.28.e34
Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999 ;73 (2):177-83. https://doi.org/10.1006/gyno.1999.5387
Suvannasarn R, Muangmool T, Wongpakaran N, Charoenkwan K. Health-related quality of life for earlystage cervical cancer survivors after primary radical surgery followed by radiotherapy versus radical surgery alone. J Obstet Gynaecol. 2022; 42 (5): 1217-24. https://doi.org/10.1080/01443615.2021.1945013 5. 2021.1945013.
Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. J Clin Oncol. 2023; 41 (29): 4605-12. https://doi.org/10.1200/JCO.22.02769
Manchana T, S i r i s a b y a N , Lertkhachonsuk R, Worasethsin P, Khemapech N, Sittisomwong T, et al. Long term complications after radical hysterectomy with pelvic lymphadenectomy. J Med Assoc Thai. 2009; 92 (4): 451-6.
Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, et al. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer. 2014; 120 (24): 3870-83. https://doi.org/10.1002/cncr.28849
Li F, Guo H, Qiu H, Liu S, Wang K, Yang C, et al. Urological complications after radical hysterectomy with postoperative radiotherapy and radiotherapy alone for cervical cancer. Medicine (Baltimore). 2018; 97 (13): e 0173. https://doi.org/10.1097/MD.0000000000010173
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019; 145 (1): 129-35. https://doi.org/10.1002/ijgo.12749
Salib MY, Russell JHB, Stewart VR, Sudderuddin SA, Barwick TD, Rockall AG, et al. 2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging. Radiographics. 2020; 40 (6): 1807-22. https://doi.org/10.1148/rg.2020200013
Suprasert P, Srisomboon J, Charoenkwan K, Siriaree S, Cheewakriangkrai C, Kietpeerakool C, et al. Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. J Obstet Gynaecol. 2010; 30 (3): 294-8. https://doi.org/10.3109/01443610903585192
Kim SI, Kim TH, Lee M, Kim HS, Chung HH, Lee TS, et al. Impact of Adjuvant Radiotherapy on Survival Outcomes in Intermediate-Risk, Early-Stage Cervical Cancer: Analyses Regarding Surgical Approach of Radical Hysterectomy. J Clin Med. 2020; 9 (11): 3545. https://doi.org/10.3390/jcm
Alonso-Espías M, Gorostidi M, Gracia M, García-Pineda V, Diestro MD, Siegrist J, et al. Role of Adjuvant Radiotherapy in Patients with Cervical Cancer Undergoing Radical Hysterectomy. J Pers Med. 2023; 13 (10): 1486. https://doi.org/10.3390/jpm13101486
Pretorius R, Semrad N, Watring W, Fotheringham N. Presentation of cervical cancer. Gynecol Oncol. 1991; 42 (1): 48-53. https://doi.org/10.1016/0090-8258(91)90229-X
Pan TL, Pareja R, Chiva L, Rodriguez J, Munsell MF, Iniesta MD, et al. Accuracy of pre-operative tumor size assessment compared to final pathology and frequency of adjuvant treatment in patients with FIGO 2018 stage IB2 cervical cancer. Int J Gynecol Cancer. 2024; 34 (12):1861-6. https://doi.org/10.1136/ijgc-2024-005986
Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. J Natl Compr Canc Netw. 2023; 21 (12): 1224-33.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Greater Mekong Subregion Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
